跳至主要内容
临床试验/EUCTR2008-002387-33-BE
EUCTR2008-002387-33-BE进行中(未招募)不适用

Impact of 25-hydroxy vitamin D deficiency and its correction on mineral and bone disorde among hemodialysis patients - VitaDial

Hôpital Erasme0 个研究点目标入组 50 人开始时间: 2008年5月27日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Written informed consent
  • Age 18 years or older
  • End-stage renal disease on hemodialysis for at least 3 months (3 dialysis sessions or more per week)
  • Serum 25-OH vitamin D levels < 30 ng/mL
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Known hypersensibility to cholecalciferol or to any constituent of the study medication (D-cure ®)
  • Pregnancy or lactation period
  • Woman of childbearing potential without effective contraception
  • Cholecalciferol, calcitriol, paricalcitol or alfacalcidol dosage adjustment 1 month prior to enrolment
  • Serum corrected calcium level > 10.2 mg/dL
  • Participation in a clinical trial or receipt of investigational compound or treatment 3 months prior the enrolment
  • Parathyroidectomy
  • History of granulomatous disorder (sarcoidosis, tuberculosis)
  • History of malignancy with a life expectancy < 12 months

研究者

相似试验

Impact of 25-hydroxy vitamin D deficiency and its ... | 临床试验